80500
document
Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar . The effect of guar ( 15.6 g/day ) , a dietary fibre , and simultaneous administration of bezafibrate ( 600 mg/day ) during dietetic treatment on the plasma lipoproteins and apolipoproteins was investigated in 12 patients with familial hypercholesterolemia ( corresponding to the HLP type IIa pattern ) . Either bezafibrate alone or bezafibrate in combination with guar was administered in a cross-over study for 3 months . Guar led to an additional lowering of the total cholesterol in the plasma by 7 % ( P less than or equal to 0.05 ) associated with a fall of the low density lipoprotein cholesterol ( LDL-cholesterol ( LDL-cholesterol ) by 13 % ( P less than or equal to 0.01 ) without any changes in the very low density lipoprotein ( VLDL ) and high density lipoprotein ( HDL ) cholesterols . In parallel with the decrease in LDL-cholesterol , the apoprotein B also was diminished by 20 % ( P less than or equal to 0.05 ) . The plasma triglyceride level and the triglyceride distribution within the individual lipoprotein fractions were not altered in any consistent manner by the addition of guar . Neither the fasting plasma glucose level nor the body weight were affected . The side-effects due to guar treatment consisted of slight nausea , meteorism and constipation , but this did not in any of the cases lead to early termination of the study . These results demonstrate that guar exerts its cholesterol-lowering effect in addition to that of bezafibrate .
80501
Intervention_Pharmacological
combination of bezafibrate and guar
80502
Intervention_Pharmacological
guar
80503
Intervention_Pharmacological
a dietary fibre
80504
Intervention_Pharmacological
bezafibrate
80505
Intervention_Pharmacological
Either bezafibrate alone or bezafibrate in combination with guar was administered in a cross-over study for 3 months
80506
Intervention_Pharmacological
Guar
80507
Intervention_Pharmacological
guar .
80508
Intervention_Pharmacological
guar treatment
80509
Intervention_Pharmacological
guar
80510
Intervention_Pharmacological
bezafibrate .
80511
Outcome_Physical
effect
80512
Outcome_Physical
total cholesterol
80513
Outcome_Physical
low density lipoprotein cholesterol ( LDL-cholesterol
80514
Outcome_Physical
LDL-cholesterol
80515
Outcome_Physical
apoprotein B
80516
Outcome_Physical
plasma triglyceride level and the triglyceride distribution
80517
Outcome_Physical
fasting plasma glucose level nor the body weight
80518
Outcome_Adverse-effects
slight nausea , meteorism and constipation
80519
Participant_Condition
12 patients with familial hypercholesterolemia ( corresponding to the HLP type IIa pattern ) .